Colorectal Study, Too
You Gotta Be Kidney? AVEO, Astellas Trying Tivo in Breast
By Randy Osborne
Staff Writer
Staff Writer
Monday, December 3, 2012
As investors continue to digest news regarding FDA concerns about overall survival trends of renal cell carcinoma patients in a Phase III trial with tivozanib, AVEO Oncology Inc. and Astellas Pharma Inc. have begun a Phase II study with the compound in triple-negative breast cancer.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.